Next-Generation Delivery and Editing
Retrotransposons are genetic elements that can replicate through reverse transcription of an RNA transposition intermediate. They contribute to structural changes and, more importantly, to gene regulation. Our proprietary RNA-based, retrotransposon-mediated gene-insertion technology (RetroT™) has applications across gene-editing and delivery.
Expanding the Ability to Reverse Genetic Errors in Situ
Our retrotransposon-based approach utilizes mRNA to deliver genetic sequences and integration enzymes in a single mRNA strand. This technology offers the potential to deliver gene-sized pieces of DNA into the genome — larger than currently possible with existing gene-editing technologies.
In March 2022, Myeloid entered into an exclusive research collaboration and option agreement with Prime Medicine to develop and accelerate RetroT™.